Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ghulam Mohi Ud Din

Gastroenterology Riverdale, MD Medical Doctor

NPI 1821142514 CMS profile 355564

6510 Kenilworth Ave, Suite 2600, Riverdale, MD 20737

Open in the dashboard

General payments

$739

48 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Ghulam Mohi Ud Din of Riverdale, MD is reported in the CMS Open Payments database as having received $739 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $61 4
2022 General $30 2
2021 General $295 16
2020 General $155 10
2019 General $197 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ghulam Mohi Ud Din
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ghulam Mohi Ud Din were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ghulam Mohi Ud Din Gastroenterology median Middle half National median
2019 $197 $417 $126–$1,100 $163
2020 $155 $224 $74–$624 $114
2021 $295 $352 $106–$1,054 $132
2022 $30 $448 $129–$1,270 $149
2023 $61 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $184 10 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $150 11 payments
  3. RedHill Biopharma Inc. $98 6 payments
  4. Gilead Sciences, Inc. $92 7 payments
  5. Celgene Corporation $52 3 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $45 3 payments
  7. Ferring Pharmaceuticals Inc. $30 2 payments
  8. Ironwood Pharmaceuticals, Inc $28 2 payments
  9. Allergan Inc. $18 1 payment
  10. Braintree Laboratories, Inc. $16 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $731 47 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2023
  1. LINZESS $154 8 payments
  2. Amitiza $104 9 payments
  3. Talicia $98 6 payments
  4. CREON $86 4 payments
  5. Movantik $66 4 payments
  6. ZEPOSIA $52 3 payments
  7. ENTYVIO $46 2 payments
  8. VIBERZI $37 2 payments
  9. MAVYRET $31 2 payments
  10. Aemcolo $30 2 payments
  11. Other $181 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

423

Median for Gastroenterology: 569

Drug cost

$9,325

Median for Gastroenterology: $104,976

Branded share of claims

18.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 45 $2,721
Famotidine Generic 130 $2,364
Omeprazole Generic 54 $1,059
Esomeprazole Magnesium Generic 15 $1,002
Pantoprazole Sodium Generic 51 $581
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 34 $503
Atorvastatin Calcium Generic 22 $311
Losartan Potassium Generic 12 $236
Celecoxib Generic 11 $198
Levothyroxine Sodium Generic 15 $105

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$24,645

Medicare's payments for the services billed

Medicare patients

138

Average age 75

Services billed

262

83 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 51%
Arthritis 49%
Chronic kidney disease 30%
Ischemic heart disease 22%
Cancer 22%
Osteoporosis 14%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record